Meeting
2024 ASCO Annual Meeting
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.
Authors
Shubham Pant
The University of Texas MD Anderson Cancer Center, Houston, TX
Shubham Pant , Jia Fan , Do-Youn Oh , Hye Jin Choi , Jin Won Kim , Heung-Moon Chang , Lequn Bao , Hui-Chuan Sun , Teresa Macarulla , Feng Xie , Jean-Philippe Metges , Ying Jieer , John A Bridgewater , Mohamedtaki Abdulaziz Tejani , Emerson Yu-sheng Chen , Harpreet Singh Wasan , Michel Pierre Ducreux , Ian Zhao , Phillip M. Garfin , James J. Harding
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04466891
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4091)
DOI
10.1200/JCO.2024.42.16_suppl.4091
Abstract #
4091
Poster Bd #
71
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.
First Author: Shubham Pant
Poster
2021 Gastrointestinal Cancers Symposium
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
First Author: Funda Meric-Bernstam
Poster
2023 ASCO Annual Meeting
ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
First Author: Kristine Peregrino Lacuna
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).
First Author: Elena Elimova